BioVie (NASDAQ:BIVI) stock is rocketing higher on Friday announed positive data from two clinical trials of NE3107.
NE3107 is BioVie’s inhibitor of inflammatory activation of ERK and NFkB. These are both factors tied to Alzheimer’s and Parkinson’s diseases.
The company’s Phase 3 of NE3107 in mild to moderate Alzheimer’s Disease patients suggests it may “realign physiological processes in patients consistent with decreased neurocognitive decline and diseases of aging.”
As for its Phase 2a trial in Parkinson’s Disease, data suggests that NE3107 patients saw “significant improvements” in non-motor symptoms and motor control. This happened while those on a placebo worsened.
What’s Next for BIVI Stock?
BioVie is planning to go into further detail about these clinical trials at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024. This will take place from March 5 to March 9.
BIVI stock is already seeing heavy trading alongside today’s study news. That has more than 62 million shares changing hands. For the record, its daily average trading volume is about 351,000 shares. The company could see another spike in trading when it makes its presentation next week.
BIVI stock is up 100% as of Friday morning.
Investors will want to keep reading for insight into today’s latest stock market news!
We have all of the hottest stock market stories that traders need to know about on Friday! Among that is what’s going on with shares of Xpeng (NYSE:XPEV), New York Community Bancorp (NYSE:NYCB) and Fisker (NYSE:FSR) stock today. You can catch up on these matters at the links below!
More Stock Market News for Friday
- XPEV Stock Alert: Xpeng Deliveries Plunged 24% YOY in February
- NYCB Stock Alert: New York Community Plunges on CEO Departure
- Fisker Layoffs 2024: What to Know About the Latest FSR Job Cuts
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
